Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2026)

Collegium Pharmaceutical's Change in Receivables history runs 11 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 10155.29% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $60000.0 (down 99.36% YoY), while the FY2025 annual figure was -$17.2 million, down 489.76% from the prior year.
• Change in Receivables was $17.4 million for Q1 2026 at Collegium Pharmaceutical, up from -$22.6 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $31.2 million in Q2 2022 to a low of -$22.6 million in Q4 2025.
• Historically, Change in Receivables has averaged $1.3 million across 5 years, with a median of -$106000.0 in 2024.
• Biggest YoY gain for Change in Receivables was 10913.68% in 2025; the steepest drop was 21240.57% in 2025.
• A 5-year view of Change in Receivables shows it stood at -$12.3 million in 2022, then jumped by 81.06% to -$2.3 million in 2023, then soared by 95.44% to -$106000.0 in 2024, then plunged by 21240.57% to -$22.6 million in 2025, then jumped by 177.07% to $17.4 million in 2026.
• The last three Change in Receivables figures came in at $17.4 million (Q1 2026), -$22.6 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.